New York State Common Retirement Fund Buys 15,277 Shares of Certara, Inc. (NASDAQ:CERT)

New York State Common Retirement Fund boosted its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 6.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 239,853 shares of the company’s stock after purchasing an additional 15,277 shares during the quarter. New York State Common Retirement Fund owned about 0.15% of Certara worth $4,219,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Covestor Ltd raised its stake in Certara by 14,940.0% during the third quarter. Covestor Ltd now owns 3,760 shares of the company’s stock valued at $55,000 after purchasing an additional 3,735 shares in the last quarter. Gamco Investors INC. ET AL purchased a new stake in Certara during the third quarter valued at $145,000. Natixis Advisors L.P. raised its stake in Certara by 13.4% during the third quarter. Natixis Advisors L.P. now owns 15,136 shares of the company’s stock valued at $220,000 after purchasing an additional 1,791 shares in the last quarter. Pacer Advisors Inc. raised its stake in Certara by 1,704.0% during the fourth quarter. Pacer Advisors Inc. now owns 12,754 shares of the company’s stock valued at $224,000 after purchasing an additional 12,047 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in shares of Certara by 31.2% in the third quarter. Commonwealth Equity Services LLC now owns 19,055 shares of the company’s stock valued at $277,000 after acquiring an additional 4,528 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Insider Buying and Selling at Certara

In other Certara news, SVP Richard M. Traynor sold 3,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $18.00, for a total transaction of $54,000.00. Following the transaction, the senior vice president now owns 173,524 shares of the company’s stock, valued at approximately $3,123,432. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Richard M. Traynor sold 3,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $18.00, for a total transaction of $54,000.00. Following the transaction, the senior vice president now directly owns 173,524 shares in the company, valued at approximately $3,123,432. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Richard M. Traynor sold 6,000 shares of Certara stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $18.00, for a total transaction of $108,000.00. Following the completion of the sale, the senior vice president now owns 165,368 shares of the company’s stock, valued at $2,976,624. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,427 shares of company stock valued at $405,095. Company insiders own 2.39% of the company’s stock.

Certara Trading Down 0.1 %

NASDAQ CERT opened at $17.60 on Monday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.62 and a current ratio of 2.62. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -50.29, a price-to-earnings-growth ratio of 1.81 and a beta of 1.61. The company’s 50-day simple moving average is $17.70 and its two-hundred day simple moving average is $16.39. Certara, Inc. has a one year low of $11.81 and a one year high of $23.54.

Certara (NASDAQ:CERT) last posted its earnings results on Thursday, February 29th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). The business had revenue of $88.01 million for the quarter, compared to analysts’ expectations of $86.80 million. Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. Equities analysts forecast that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. SVB Leerink assumed coverage on shares of Certara in a research note on Monday, February 26th. They issued a “market perform” rating and a $19.00 target price on the stock. Jefferies Financial Group increased their target price on shares of Certara from $14.00 to $15.50 and gave the company a “hold” rating in a research note on Friday, March 1st. Leerink Partnrs reissued a “market perform” rating on shares of Certara in a research note on Monday, February 26th. KeyCorp raised shares of Certara from a “sector weight” rating to an “overweight” rating and set a $23.00 target price on the stock in a research note on Wednesday, April 10th. Finally, Barclays raised their price target on shares of Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Certara presently has a consensus rating of “Hold” and a consensus target price of $20.06.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.